1396 related articles for article (PubMed ID: 12236627)
1. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
2. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
3. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
[TBL] [Abstract][Full Text] [Related]
4. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
5. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
[TBL] [Abstract][Full Text] [Related]
6. Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset.
Ongur D; Farabaugh A; Iosifescu DV; Perlis R; Fava M
Psychother Psychosom; 2005; 74(3):173-8. PubMed ID: 15832068
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
8. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-GĂ©linier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
11. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
13. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
14. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
[TBL] [Abstract][Full Text] [Related]
16. An open-label trial of nefazodone in high comorbidity panic disorder.
DeMartinis NA; Schweizer E; Rickels K
J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
18. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Schatzberg A; Roose S
Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
Gao K; Muzina D; Gajwani P; Calabrese JR
J Clin Psychiatry; 2006 Sep; 67(9):1327-40. PubMed ID: 17017818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]